1246397-34-1

Basic information

• Product Name: (2E)-1-((10R,13S)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3(β)-hydroxy-10,13-dimethyl-1H-cyclopenta[α]phenanthren-17(β)-yl)-3-(4-methoxyphenyl)prop-2-en-1-one
• Synonyms: (2E)-1-((10R,13S)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3(β)-hydroxy-10,13-dimethyl-1H-cyclopenta[α]phenanthren-17(β)-yl)-3-(4-methoxyphenyl)prop-2-en-1-one
• CAS NO: 1246397-34-1
• Molecular Weight: 434.619
• Mol File: 1246397-34-1.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (2E)-1-((10R,13S)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3(β)-hydroxy-10,13-dimethyl-1H-cyclopenta[α]phenanthren-17(β)-yl)-3-(4-methoxyphenyl)prop-2-en-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-1-((10R,13S)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3(β)-hydroxy-10,13-dimethyl-1H-cyclopenta[α]phenanthren-17(β)-yl)-3-(4-methoxyphenyl)prop-2-en-1-one(1246397-34-1)
• EPA Substance Registry System: (2E)-1-((10R,13S)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3(β)-hydroxy-10,13-dimethyl-1H-cyclopenta[α]phenanthren-17(β)-yl)-3-(4-methoxyphenyl)prop-2-en-1-one(1246397-34-1)

Safety Data

• Hazardous Substances Data: 1246397-34-1(Hazardous Substances Data)

Upstream product

• 24680-50-0 4-methoxy-trans-cinnamaldehyde 
• 145-13-1 Pregnenolone 
• 123-11-5 4-methoxy-benzaldehyde 

Downstream Products

• 1369424-68-9 1-(4,5-dihydro-3-((10R,13S)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3-hydroxy-10,13-dimethyl-1H-cyclopenta[a]phenanthren-17-yl)-5-(4-methoxyphenyl) pyrazol-1-yl)ethanone 
• 1365727-35-0 C₂₉H₃₈O₄ 

Relevant articles and documents

Benzylidine pregnenolones and their oximes as potential anticancer agents: Synthesis and biological evaluation

The present study reveals the anticancer activity of benzylidine pregnenolones and their oxime derivatives. The synthesis of the analogs of both series is very simple and involves aldol condensation in the first step followed by nucleophillic addition of hydroxylamine across carbonyl in the second step. Quantitative yields of more than 80% are obtained in both the steps. All the compounds were tested for their cytotoxic activities against a panel of six human cancer cell lines. Amongst all the compounds of both the series screened for their cytotoxic activity, compound 3e, 3f and 4e are very potent especially against HCT-15 and MCF-7 cancer cell lines.

Steroidal pyrazolines and pyrazoles as potential 5α-reductase inhibitors: Synthesis and biological evaluation

Taking pregnenolone as the starting material, two series of pyrazolinyl and pyrazolyl pregnenolones were synthesized through different routes. The synthesis of the analogs of both series is multistep and proceeds in good overall yields. While the key step in the synthesis of pyrazolinyl pregnenolones is the heterocyclization of benzylidine derivatives (3) in presence of hydrazine hydrate, it is the condensation of 3β-hydroxy-21-hydroxymethylidenepregn-5-en-3β-ol-20-one (5) with phenylhydrazine in the synthesis of pyrazolyl derivatives. Compounds of both the series were tested for their 5α-reductase inhibitory activities. Amongst all the compounds screened for their 5α-reductase inhibitory activities, compound 4b, 4c and 6b were found to be the most active.

Synthesis of D-ring-substituted (5′R)- and (5′S)-17β- pyrazolinylandrostene epimers and comparison of their potential anticancer activities

Various steroidal benzylidenes were synthetized from pregnenolone with benzaldehyde and p-substituted benzaldehydes. The resulting 17β-chalconyl derivatives of pregnenolone were reacted with hydrazine hydrate in acetic acid solution. Regardless of the sta